161 results about "Myocardial ischaemia" patented technology

The invention discloses injectable hydrogel with redox activity and electroactivity as well as a preparation method and application of the injectable hydrogel, and belongs to the technical field of medical materials. The preparation method comprises the following steps: reacting methacrylic anhydride and polysaccharide molecules in a solvent to prepare a double-bond functional polymer; the preparation method comprises the following steps: firstly, pre-polymerizing dopamine in a solvent, and then adding MOF (Metal Organic Framework) to carry out polymerization reaction, so as to prepare dopamine modified MOF; reacting the dopamine modified MOF, EDOT and ferric salt in a solvent, and collecting the precipitate to prepare a nano filler; the preparation method comprises the following steps: jointly dispersing the double-bond functional polymer, active polypeptide, a photoinitiator and nano filler into a solvent, and carrying out photocuring cross-linking. The preparation condition is mild, gel forming is rapid, the method is simple, the prepared hydrogel has injectable performance and conductive performance, catalytic activity of natural enzyme can be simulated, active oxygen removal can be achieved in the early stage of myocardial ischemia, electrical conduction of infarction parts can be enhanced, and effective recovery of cardiac functions can be achieved.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention provides a portable dynamic high-frequency electrocardio monitoring system and method, and provides an efficient solution aiming at the problems that traditional high-frequency electrocardio depends on exercise load, diagnosis is delayed, the detection rate is low and the like in myocardial ischemia diagnosis. Electrocardio acquisition hardware of the system adopts a high signal-to-noise ratio and high-fidelity design so as to enhance the detection capability of high-frequency electrocardiosignals, and data is transmitted to a mobile terminal in real time through a wireless module, so that continuous dynamic monitoring is realized. A software algorithm preprocesses the collected dynamic resting high-frequency electrocardio data, abnormal waveforms are removed, and high-frequency signals are extracted with 3 seconds as a unit. Then, the data are input into a pre-trained electrocardiogram classification network, the network integrates a multi-scale convolution module, a feature splicing module, a long-short term memory network module, a self-adaptive convolution module and other modules, automatic feature extraction and time sequence modeling are achieved, and early myocardial ischemia can be efficiently recognized. The system provides an efficient and real-time solution for early diagnosis and intervention of myocardial ischemia.

The invention discloses application of chrysin-7-0-beta-D-glucuronide in treatment of ischemic heart disease or an LRP6 inhibitor, and belongs to the technical field of treatment of ischemic heart disease. The invention provides a new application of a small molecular compound chrysin-7-0-beta-D-glucuronide, the compound realizes regulation and control on a cardiac muscle cell cycle by inhibiting LRP6, and finally promotes repair of cardiac muscle cells and inhibits apoptosis. According to the invention, by exploring the function of inhibiting LRP6 protein of a small molecule drug, a powerful repair reaction is guided after myocardial ischemia reperfusion, so that effective treatment of myocardial infarction is realized. Therefore, finding of an LRP6 inhibitor not only has a potential curative effect on promoting myocardial cells to enter a cell cycle, but also has important significance on treatment of MI.

The invention relates to application of an MYZAP overexpression vector in preparation of a medicine for preventing and treating MIRI, and belongs to the technical field of biological medicine. In order to solve the problem that application of gene drugs in prevention and treatment of myocardial ischemia reperfusion injury is limited, the invention provides application of an MYZAP gene overexpression recombinant vector in preparation of drugs for prevention and treatment of myocardial ischemia reperfusion injury, and the MYZAP gene overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP for overexpressing MYZAP. Experiments prove that MYZAP overexpression can improve the cardiac function after myocardial ischemia reperfusion, reduce the occurrence rate of arrhythmia and improve the functions of sodium ion channels, potassium ion channels and calcium ion channels of myocardial cells. On the basis, the invention further provides a medicine for preventing and treating myocardial ischemia reperfusion injury, a new strategy is provided for gene therapy of myocardial ischemia reperfusion injury, and the medicine has a wide clinical application prospect.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and / or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

The invention provides a nanoparticle capable of releasing EGCG (epigallocatechin gallate) in response to ROS (reactive oxygen species) as well as a preparation method and application of the nanoparticle. The nanoparticles comprise a carrier and EGCG (epigallocatechin gallate) loaded on the carrier; the carrier is Prussian blue nanoparticles of which the surfaces are modified with polyethyleneimine and phenylboronic acid compounds. The preparation method of the nanoparticles is simple and easy to operate, the nanoparticles are good in dispersity, and through research, the nanoparticles have CAT-like, SOD-like and other multi-enzyme activities, can remove. OH, have a high EGCG drug loading rate and release EGCG in the presence of ROS. Besides, the nanoparticles show a good effect of improving myocardial ischemia reperfusion injury in cell level and rat in-vivo experiments, through comparison of EGCG and PB NPs single-drug treatment, synergistic treatment in the composite material achieves an effect of '1 + 1 > 2', and the composite material has good biological safety.

The invention discloses a ginsenoside hydrogen sulfide donor derivative as well as a preparation method and application thereof, and belongs to the technical field of natural medicines and medicinal chemistry. According to the invention, a series of ginsengenin hydrogen sulfide donor derivatives are designed and synthesized by taking ginsengenin as a lead compound, and the myocardial protection activity of the synthesized derivatives is tested; results show that the ginsenoside hydrogen sulfide donor derivative prepared by the invention has relatively good heart protection activity for treating myocardial ischemia, arrhythmia and myocardial infarction, and has the potential of serving as a heart protection medicine.

The invention discloses a medicine prepared from apoptotic fibroblast-derived vesicles and used for preventing and treating myocardial ischemia-reperfusion injury as well as a preparation method and application of the medicine, and relates to the technical field of biological medicines. The method comprises the following steps: digesting an in-vitro animal heart apex tissue to obtain a digested cell suspension; the myocardial fibroblasts are obtained; the method comprises the following steps: culturing myocardial fibroblasts in a DMEM (dulbecco's modified eagle medium) solution through apoptosis inducer H2O2 to obtain a culture solution; according to the method, apoptosis of fibroblasts is induced to generate specific extracellular vesicles, the surface of the extracellular vesicles carries CD22 as a marker, the content of the extracellular vesicles is enriched in miR-1246 and is taken by myocardial cells, expression of p53 is down-regulated, mitochondrial homeostasis is maintained, and the extracellular vesicles can be used for detecting apoptosis of the fibroblasts. The myocardial cell apoptosis is inhibited.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention discloses a real-time multi-mode physiological signal analysis method for myocardial ischemia, and belongs to the technical field of data analys.The technical scheme includes that electrocardiogram, photoelectric volume pulse waves and thoracic impedance signals are synchronously acquired, and phase difference caused by motion displacement is compensated in real time by the aid of a triaxial accelerometer; constructing a multi-dimensional quality evaluation matrix containing an electrocardiogram signal-to-noise ratio, a photoelectric volume pulse wave perfusion index and a chest impedance variance, and jointly judging whether signal reconstruction is triggered or not based on a dynamic threshold value and accelerometer data; a multi-channel signal block which is judged to be low in quality through the quality evaluation matrix and comprises the electrocardiogram and photoelectric volume pulse waves and chest impedance synchronized with the electrocardiogram is input into a generative adversarial network with electrophysiological constraints to be reconstructed, and a reconstructed high-quality electrocardiogram signal is output; and myocardial ischemia key indexes are extracted from the reconstructed signals, and multi-level risk early warning is carried out. The real-time multi-modal physiological signal analysis method for myocardial ischemia has the beneficial effect that the real-time multi-modal physiological signal analysis method for myocardial ischemia is provided.

The invention discloses an application of Evaixin in prevention or treatment of mitochondrial abnormality diseases. The invention provides an application of an Avaixin oral liquid in preparation of a product for improving mitochondrial homeostasis imbalance. The mitochondrial homeostasis imbalance is caused by cardiovascular diseases. The invention proves that the Avaifuxin oral liquid has a potential protection effect on cardiovascular diseases, and plays a protection role by adjusting the dynamic balance of mitochondrial fusion and division processes. The invention is of great significance to further understanding the protective action mechanism of the Aiwei heart oral liquid on the mitochondrial homeostasis imbalance caused by cardiovascular diseases (hypertensive myocardial hypertrophy, myocardial fibrosis, ventricular remodeling, heart failure, myocardial infarction and myocardial ischemia-reperfusion injury) and improving the corresponding curative effect.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving cognitive impairment of coronary heart disease and application thereof. The composition is prepared from the following raw material components: fructus alpiniae oxyphyllae, fructus lycii, diaphragma juglandis, lotus plumule, ginseng, ligusticum wallichii and radix paeoniae rubra. The composition can improve the cardiac function and the cardiac structure after coronary heart disease acute myocardial ischemia injury, reduce the ischemic myocardial infarction area, relieve myocardial cell injury and myocardial fibrosis, relieve hippocampal neuron injury and ultrastructure change, and improve learning and memory functions and cognitive behavior performance.

The invention discloses application of a Cpeb3 gene inhibitor and a copper death inhibitor in preparation of a medicine for treating myocardial ischemia-reperfusion injury, and relates to the technical field of myocardial ischemia-reperfusion injury. By specifically reducing or knocking out Cpeb3 expression, myocardial repair can be remarkably promoted, action potential stability is improved, and the death rate is reduced. Therefore, Cpeb3 is a specific intervention target spot of copper death in Gpc6 + CMs. The small molecule inhibitor of Cpeb3 can remarkably reverse changes of copper death, aerobic respiration and / or glycolysis caused by Cpeb3 activation. In addition, the copper death inhibitor can improve the survival rate of myocardial cells, reverse the change of aerobic respiration and / or glycolysis induced by Cu, and reverse the change of glycolysis, pentose phosphate pathway and tricarboxylic acid cycle metabolites caused by Cu stimulation. Therefore, the invention provides a new solution for prevention and treatment of myocardial ischemia reperfusion injury, and has a good application prospect.

The invention relates to a nano drug-loaded complex with a targeted myocardial function as well as a preparation method and application of the nano drug-loaded complex. The preparation method comprises the following steps: constructing a novel, safe and efficient nano drug-loaded complex by utilizing a nano material assembly technology, namely preparing phospholipid micelles by taking distearoyl phosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG) as a main raw material, loading fluorescent coumarin 6 (C6), adding ischemia targeting polypeptide CSTSMLKAC (PEP) to be coupled on the outer side of the DSPE-PEG, wrapping an SIRT6 agonist MDL-800 in the DSPE-PEG, and preparing the novel, safe and efficient nano drug-loaded complex. The preparation method comprises the following steps: designing and constructing to obtain a DSPE-PEG-C6-PEP-MDL-800 (DPCP-MDL-800) complex; on the basis, characterization release and in-vivo distribution of the complex and an improvement effect of the complex on myocardial ischemia reperfusion injury of an aged mouse are evaluated. The novel nano drug-loaded complex drug with the ischemic myocardial targeting function provided by the invention is expected to provide a potential solution for myocardial ischemia reperfusion injury of aged mice.

The invention belongs to the field of traditional Chinese medicine chemistry and natural product separation, and particularly relates to extraction and separation of a novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol and application of the novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol in myocardial protection drugs. The compound is named as 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol, and the structural formula of the compound is shown in the description. The invention provides an extraction and separation method of the compound. The extraction and separation method mainly comprises the following steps: sequentially carrying out solvent extraction, macroporous adsorption resin enrichment, silica gel column chromatography, ODS medium-pressure column chromatography, high performance liquid chromatography separation and purification and the like on ginseng and other traditional Chinese medicine processed products and hydrolysates. The structure of the compound is determined through comprehensive analysis of a high-resolution mass spectrum (HRMS), one-dimensional nuclear magnetic resonance (1H NMR, 13C NMR) and a two-dimensional nuclear magnetic resonance spectrum (such as HSQC, HMBC, ROESY and the like), and the compound is a newly discovered dammarane type triterpene compound. Experiments show that the compound and the composition thereof have a remarkable protection effect on myocardial cell hypoxia / reoxygenation reperfusion injury, and can be used for preparing drugs for preventing or treating myocardial ischemia reperfusion injury and other related diseases.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

Compositions and methods are provided for treating ischemic conditions such as myocardial infarction, myocardial ischemia, or ischemia reperfusion injury in a subject in need thereof. In particular, the methods comprise administering a therapeutically effective amount of programmed death ligand-1 (PD-L1) to a subject.

The invention discloses a PH response type modified polydopamine nano preparation loaded with icariin and application of the PH response type modified polydopamine nano preparation in myocardial ischemia resistance, and belongs to the technical field of biological medicine. The nano preparation takes polydopamine (PDA) as a carrier core, the carrier core is modified by methoxy polyethylene glycol (mPEG) and then loaded with icariin (ICA), and the nano preparation is named as mPEG-PDA (at) ICANPs; the preparation process comprises the steps of synthesis of mPEG-OTs, synthesis of mPEG-EDA, synthesis of PDA, preparation of mPEG-PDANPs and preparation of mPEG-PDA (at) ICANPs, under the optimal condition, the particle size of the preparation is 179.6 + / -0.432 nm, PDI is 0.130 + / -0.004, the Zeta potential is 23.4 + / -0.436 mV, the stability is good after the preparation is stored in a dark place at 4 DEG C for 30 days, the ICA drug loading capacity is 14.6 + / -1.08%, the encapsulation efficiency is 64.37 + / -2.31%, and the drug cumulative release rate reaches 73.31 + / -1.64% (pH response drug release) in an environment with the pH value of 6.5 for 72 hours. An in-vitro H9c2 cell OGD model experiment proves that the preparation can remarkably improve the survival rate of ischemic myocardial cells, inhibit apoptosis and reduce LDH release, and the effect of the preparation is superior to that of free ICA. The invention provides an efficient targeting drug delivery system for resisting myocardial ischemia, and has important clinical application value.

Electrocardiography (ECG) data acquired from a subject and processed with a machine learning model to determine whether the subject has a particular cardiac condition, such as a cardiac arrhythmia, myocardial ischemia and / or myocardial infarction, or the like. The machine learning model generates classified feature data that are indicative of the presence and / or likelihood of a particular cardiac condition.

The application relates to the field of myocardial ischemia-reperfusion injury drugs, and discloses application of Gualou Xiebai Baijiu decoction in preparation of myocardial ischemia-reperfusion injury drugs. The myocardial ischemia-reperfusion injury drugs inhibit the GSK-3beta / Drp1-mediated mitochondrial fission pathway by targeting Akt protein, maintain the dynamic balance of mitochondrial dynamics, and play a myocardial protection role. The drugs can promote Akt phosphorylation activation, inhibit GSK-3beta activity, down-regulate Drp1 protein Ser616 site phosphorylation, up-regulate Ser637 site phosphorylation, reduce Drp1 translocation and aggregation to the outer membrane of mitochondria, and simultaneously up-regulate the expression of mitochondrial fusion proteins Mfn1 and Mfn2. The drugs can maintain the structural integrity of mitochondria, improve the mitochondrial membrane potential and ATP content, improve myocardial cell energy metabolism, regulate the expression of apoptosis-related proteins to inhibit myocardial cell apoptosis, improve the cardiac systolic function after ischemia-reperfusion, reduce the myocardial infarction area, reduce the serum myocardial injury marker level, and regulate the oxidative stress state.

The invention relates to the field of biological medicine, in particular to a GDF-15 defect-based modeling method which comprises the following steps: ligating left coronary anterior descending branches of a plurality of GDF-15 knockout mice, and respectively establishing myocardial ischemia reperfusion models based on recombinant GDF-15 and normal saline; the method comprises the following steps: taking a myocardial tissue sample, and treating the sample at a pre-plating temperature and a pre-plating duration to obtain myocardial cells; detecting an AMPK signal channel expressed by the myocardial tissue protein; determining whether the activity of the AMPK signal path is inhibited or not based on the phosphorylation state value, and determining the osmotic pump rate; or, detecting the ROS level of the myocardial cells to obtain a captured image, determining the state of the myocardial cells based on the gray value of the image, and determining the stability of the state of the myocardial cells according to the oxidative stress index of the captured image; carrying out an anoxic experiment to obtain a fluorescence image; and determining the myocardial cell purity based on the fluorescence signal intensity, adjusting the osmotic pump rate, or adjusting the pre-plating time length or the pre-plating temperature, so that the accuracy of GDF-15 defect modeling drug administration is improved.

The application provides an antisense oligonucleotide Jag-i9 ASO and application thereof, relates to the technical field of biological medicine, and the antisense oligonucleotide Jag-i9 ASO has the sequence of 5'-ACTGGGCCCTGCACCTGA-3'. By providing the antisense oligonucleotide of a specific sequence, the binding site of target heterogeneous ribonucleoprotein K and the Jag2 gene is targeted, the expression of the pro-inflammatory Jag2 subtype is inhibited, the Jag2 gene splicing site can be accurately targeted, the heterogeneous ribonucleoprotein K binding function is specifically blocked, a targeted intervention means is provided for the treatment of myocardial ischemia-reperfusion injury, the generation of the pro-inflammatory subtype is inhibited by efficiently and accurately regulating the alternative splicing of a specific gene, myocardial cell apoptosis and inflammatory response are reduced, myocardial function is improved, and a new approach is provided for the prevention and treatment of myocardial ischemia-reperfusion injury, the treatment effect is improved, and the advantages of reducing side effects are achieved.

The application discloses a magnetocardiogram gradient instrument and an electrocardio collection circuit packaging structure and a signal processing system, relates to the technical field of medical equipment, and realizes high-density integration of hardware and reliable protection through a rigid protection frame formed by a circuit chip, a layer plate structure and a connecting assembly, shortens a signal transmission path, reduces the influence of environmental vibration, dust, moisture and electromagnetic disturbance on a synchronous sampling link, and provides a stable data basis for multi-modal fusion imaging. The signal processing system comprises multi-modal synchronous collection, noise suppression, data fusion imaging and a diagnosis auxiliary module, generates a high-precision space-time dynamic imaging atlas by constructing a cardiac electromagnetic field joint forward model and applying time and space double constraints, and outputs a cardiovascular risk assessment, a cardiac arrhythmia positioning and a myocardial ischemia quantification result in combination with machine learning. The application solves the problems of low integration, poor anti-interference and insufficient single modal detection precision of existing equipment.

The invention discloses a medicine for treating the heart of a human body, and particularly relates to the field of medicines, the medicine is prepared from the following components in percentage by mass: 13.8% of radix salviae miltiorrhizae, 4.1% of allium macrostemon, 8.3% of semen trichosanthis, 2% of polygala tenuifolia, 8.3% of radix ophiopogonis, 2% of sandalwood, 6.9% of pericarpium citri reticulatae viride, 13.8% of lily, 8.3% of semen boitae, 10.4% of poria cocos, 8.3% of oriental cherry powder and 13.8% of earthworm, and the sum of the mass percentages of the components is 100%. According to the medicine for treating the heart of the human body, traditional Chinese medicine decoction pieces such as salvia miltiorrhiza, allium macrostemon, snakegourd seeds, polygala tenuifolia, radix ophiopogonis, sandalwood, pericarpium citri reticulatae viride, lily, platycladi seeds, poria cocos, oriental cherry powder and lumbricus are crushed and proportioned according to corresponding formula proportions and processes, so that the medicine plays the maximum effects of all the decoction pieces, is easier to take and absorb, and can be taken for a long time after being taken. The traditional Chinese medicine composition has obvious treatment effects on cardiac insufficiency, dyspnea, weakness, fatigue, angina pectoris, palpitation, palpitation and other problems caused by heart problems of heart disease patients, and can effectively treat coronary heart disease, myocardial ischemia, arrhythmia and other heart diseases.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary diseases, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension, Alzheimer disease, vascular dementia, glaucoma, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ischemic optic neuropathy or chronic kidney disease. The present invention relates to a compound of the formula [I], the formula [II] or the formula [III], or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the DESCRIPTION.

The invention provides an anti-rotation medical wrist strap integrated with an electrocardiograph monitoring function, the anti-rotation medical wrist strap comprises a wrist strap main body and a function box which can form closed ring type connection, the wrist strap main body is formed by weaving an SMPU base body and shape memory alloy wires, and an electrode array and a miniature myoelectricity sensor array which are arranged in a coplanar mode are integrated on an inner ring layer, facing a human body, of the wrist strap main body; an intelligent main control module, a wireless energy data transmission module and a parameter detection module are integrated in the function box, and the intelligent main control module is pre-trained with a clinical diagnosis model, automatically identifies abnormal states of arrhythmia, myocardial ischemia and hyperlactic acid and executes early warning grading pushing. The system integrates electrocardiograph monitoring, rotation prevention and multi-module cooperation, adapts to all scenes inside and outside a hospital, integrates advanced technologies such as biological intelligent detection and wireless energy data transmission, and constructs an intelligent closed loop of'perception-decision-execution 'of multi-signal fusion diagnosis early warning, emergency rescue linkage and full-period management inside and outside the hospital; and the medical service efficiency and accuracy are greatly improved.

Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.

The present invention discloses a pharmaceutical composition comprising more than 26 substances, obtained by mixing ethanol extracts of costus root, agarwood, jujube, terminalia chebula, nutmeg, kapok, and frankincense with travertine. The composition can improve myocardial ischemia in subjects; increase the ejection fraction of subjects with myocardial infarction; increase the fractional shortening of the heart; reduce the left ventricular end-diastolic diameter in subjects with myocardial infarction; reduce the left ventricular end-systolic diameter in subjects with myocardial infarction; shorten the sleep latency in subjects with insomnia; prolong the sleep duration in subjects; and upregulate the expression of GAD67 protein in the brain tissue of subjects.